These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12957798)

  • 21. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
    Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
    Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.
    Wankowicz-Kalinska A; Mailliard RB; Olson K; Graham F; Edington H; Kirkwood JM; Martinek S; Das PK; Storkus WJ
    Melanoma Res; 2006 Apr; 16(2):165-74. PubMed ID: 16567972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma.
    Melief SM; Visser M; van der Burg SH; Verdegaal EME
    Cancer Immunol Immunother; 2017 Jul; 66(7):913-926. PubMed ID: 28401257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
    Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
    Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Future of malignant stage I melanoma. Immunology and immunotherapy].
    Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP
    Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476
    [No Abstract]   [Full Text] [Related]  

  • 26. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T cell triumph. Immunotherapy may have finally turned a corner.
    Martindale D
    Sci Am; 2003 Feb; 288(2):12-3. PubMed ID: 12561452
    [No Abstract]   [Full Text] [Related]  

  • 28. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
    Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
    J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
    López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
    J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor immunotherapy in melanoma: on the dawn of a new era?
    Wilcox R; Markovic SN
    Curr Opin Mol Ther; 2007 Feb; 9(1):70-8. PubMed ID: 17330404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes.
    De Palma R; Marigo I; Del Galdo F; De Santo C; Serafini P; Cingarlini S; Tüting T; Lenz J; Basso G; Milan G; Zanovello P; Bronte V
    Cancer Res; 2004 Nov; 64(21):8068-76. PubMed ID: 15520218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active-specific immunization against melanoma: is the problem at the receiving end?
    Monsurrò V; Wang E; Panelli MC; Nagorsen D; Jin P; Katia Z; Smith K; Ngalame Y; Even J; Marincola FM
    Semin Cancer Biol; 2003 Dec; 13(6):473-80. PubMed ID: 15001166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
    Baumgaertner P; Rufer N; Devevre E; Derre L; Rimoldi D; Geldhof C; Voelter V; Liénard D; Romero P; Speiser DE
    Cancer Res; 2006 Feb; 66(4):1912-6. PubMed ID: 16488988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive T-cell transfer in melanoma.
    Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
    Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
    Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ
    Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunotherapeutic possibilities for treatment of malignant melanomas].
    Kokoschka EM
    Hautarzt; 1979 Dec; 30(12):656-61. PubMed ID: 317654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.